TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Aequus Pharmaceuticals ( (TSE:AQS) ).
Aequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, scheduled for November 21, 2025. The company clarified details about a potential share consolidation, stating it will not proceed if certain conditions affecting the market price of shares arise. Additionally, Aequus addressed a cease trade order involving director nominee Marc Lustig due to a failure to file insider reports, and a separate cease trade order related to PharmaCielo Ltd., where Lustig was CEO, which has since been resolved. These disclosures aim to ensure transparency and compliance with regulatory requirements.
Spark’s Take on TSE:AQS Stock
According to Spark, TipRanks’ AI Analyst, TSE:AQS is a Underperform.
Aequus Pharmaceuticals is experiencing severe financial difficulties with declining revenues, negative net income, and cash flow issues. These problems significantly impact the stock’s attractiveness. The lack of technical analysis data and poor valuation metrics further contribute to a low overall stock score. The company may require drastic strategic measures to improve its financial health.
To see Spark’s full report on TSE:AQS stock, click here.
More about Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on commercializing value-added products in specialty therapeutic areas within the Canadian market.
Average Trading Volume: 10,000
Technical Sentiment Signal: Sell
Current Market Cap: C$663.2K
For a thorough assessment of AQS stock, go to TipRanks’ Stock Analysis page.